(VIANEWS) – Bank Of Montreal (BMO), Neurocrine Biosciences (NBIX), NextEra Energy (NEE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Bank Of Montreal (BMO)
28.7% sales growth and 10.1% return on equity
Bank of Montreal provides diversified financial services primarily in North America. The company's personal banking products and services include checking and savings accounts, credit cards, mortgages, and financial and investment advice services; and commercial banking products and services comprise business deposit accounts, commercial credit cards, business loans and commercial mortgages, cash management solutions, foreign exchange, specialized banking programs, treasury and payment solutions, and risk management products for small business and commercial banking customers. It also offers investment and wealth advisory services; digital investing services; financial services and solutions; and investment management, and trust and custody services. In addition, the company provides life insurance, accident and sickness insurance, and annuity products; creditor and travel insurance to bank customers; and reinsurance solutions. Further, it offers client's debt and equity capital-raising services, as well as loan origination and syndication, and treasury management; strategic advice on mergers and acquisitions, restructurings, and recapitalizations, as well as valuation and fairness opinions; and trade finance, risk mitigation, and other operating services. Additionally, the company provides research and access to markets for institutional, corporate, and retail clients; trading solutions that include debt, foreign exchange, interest rate, credit, equity, securitization and commodities; new product development and origination services, as well as risk management advice and services to hedge against fluctuations; and funding and liquidity management services to its clients. Bank of Montreal was founded in 1817 and is headquartered in Montreal, Canada.
Earnings Per Share
As for profitability, Bank Of Montreal has a trailing twelve months EPS of $7.53.
PE Ratio
Bank Of Montreal has a trailing twelve months price to earnings ratio of 11.97. Meaning, the purchaser of the share is investing $11.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.1%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 19.8%, now sitting on 29.96B for the twelve trailing months.
Sales Growth
Bank Of Montreal’s sales growth is 25.8% for the current quarter and 28.7% for the next.
Yearly Top and Bottom Value
Bank Of Montreal’s stock is valued at $90.17 at 06:22 EST, way below its 52-week high of $105.40 and way above its 52-week low of $81.57.
2. Neurocrine Biosciences (NBIX)
23.9% sales growth and 4.16% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $0.62.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 152.1. Meaning, the purchaser of the share is investing $152.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.16%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Neurocrine Biosciences’s EBITDA is -89.46.
Volume
Today’s last reported volume for Neurocrine Biosciences is 1052040 which is 41.49% above its average volume of 743496.
3. NextEra Energy (NEE)
23.3% sales growth and 11.77% return on equity
NextEra Energy, Inc., through its subsidiaries, generates, transmits, distributes, and sells electric power to retail and wholesale customers in North America. The company generates electricity through wind, solar, nuclear, coal, and natural gas facilities. It also develops, constructs, and operates long-term contracted assets that consists of clean energy solutions, such as renewable generation facilities, battery storage projects, and electric transmission facilities; sells energy commodities; and owns, develops, constructs, manages and operates electric generation facilities in wholesale energy markets. As of December 31, 2022, the company had approximately 32,100 megawatts of net generating capacity; approximately 88,000 circuit miles of transmission and distribution lines; and 871 substations. It serves approximately 12 million people through approximately 5.8 million customer accounts in the east and lower west coasts of Florida. The company was formerly known as FPL Group, Inc. and changed its name to NextEra Energy, Inc. in 2010. NextEra Energy, Inc. was founded in 1925 and is headquartered in Juno Beach, Florida.
Earnings Per Share
As for profitability, NextEra Energy has a trailing twelve months EPS of $3.37.
PE Ratio
NextEra Energy has a trailing twelve months price to earnings ratio of 21.16. Meaning, the purchaser of the share is investing $21.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.77%.
Moving Average
NextEra Energy’s worth is under its 50-day moving average of $75.09 and under its 200-day moving average of $78.18.
Previous days news about NextEra Energy(NEE)
- The zacks analyst blog highlights honeywell international, humana, keurig dr pepper, nextera energy and the Coca-Cola. According to Zacks on Tuesday, 11 July, "Stocks recently featured in the blog include: Honeywell International Inc. (HON Quick QuoteHON – Free Report) , Humana Inc.’s (HUM Quick QuoteHUM – Free Report) , Keurig Dr Pepper Inc. (KDP Quick QuoteKDP – Free Report) , NextEra Energy Inc. (NEE Quick QuoteNEE – Free Report) and The Coca-Cola Co. (KO Quick QuoteKO – Free Report) ."
- According to MarketWatch on Tuesday, 11 July, "It is interesting to see NextEra Energy Inc. among the fund’s largest holdings. "
4. Synopsys (SNPS)
22.5% sales growth and 15.85% return on equity
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as a series of tools used in the design of optical systems and photonic devices. Further, it provides security testing, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. The company serves electronics, financial services, automotive, medicine, energy, and industrial areas. Synopsys, Inc. was incorporated in 1986 and is headquartered in Mountain View, California.
Earnings Per Share
As for profitability, Synopsys has a trailing twelve months EPS of $5.99.
PE Ratio
Synopsys has a trailing twelve months price to earnings ratio of 72.82. Meaning, the purchaser of the share is investing $72.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.85%.
